Partnering

We have flexibility around potential collaboration and partnership structures, depending on the nature of the target, existing funding sources, and anticipated milestones. We foster collaborative team structures with our partners to effectively and efficiently prosecute rapid achievement of target objectives.

Ansaris' proprietary computational chemistry platform suite of tools combines virtual homology modeling, novel binding information, and rapid fragment screening, to identify patentable lead compounds with optimal drug properties.

Unique Benefits of Partnering with Ansaris:

Ansaris' integrated design teams proactively engage in-house computational chemistry, medicinal chemistry, and biology resources for optimal design efficiency. Our design teams are made up of relatively fewer FTEs than typical drug discovery efforts, and support efficient ADME and screening assay turnaround time to allow rapid iterative design improvements.

We have established design experience with over 40 targets, including kinases, proteases, nuclear hormone receptors, growth factor receptors, surface proteins, cytokines, fungicides, and phosphatases. Using our computational platform, we are able to initiate design with or without target structural information. We have demonstrated experience with the identification of innovative allosteric binding sites and the design of novel, prospectively optimized, and chemically diverse therapeutics.

Unique Benefits of the Charrette™ FBDD Platform:

• Demonstrated ability to design novel compounds prospectively
• Protein models sufficient for lead design and selectivity, in advance of crystal structure, with excellent SAR correlation.
• Whole molecule energy is uniquely integrated over a distribution of poses for better compound design.
• Combinatorics that provide a vast, diverse search of chemical space (ex. 5000 fragments generate 125 billion hit-like molecules).
• The ability to build in desired physicochemical properties prospectively (MW, LogP, predicted binding affinity, # of rotatable bonds, druggability) with tools that allow informed medicinal chemistry decisions.